High Intensity Interval Training in Chronic Stroke
Launched by UNIVERSITY OF CINCINNATI · Oct 7, 2013
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
Participants were randomized to either HIT or traditional aerobic training; each 25 minutes, 3 times per week for 4 weeks. Outcomes were measured before and after training by a blinded rater.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) age 35-90 years
- • 2) unilateral stroke experienced \>6 months prior to enrollment
- • 3) able to walk 10m overground with assistive devices as needed and no physical assistance
- • 4) able to walk 3 minutes on the treadmill at \>.13m/s (0.3mph) with no aerobic exercise contraindications
- • 5) stable cardiovascular condition (American Heart Association class B, allowing for aerobic capacity \<6 metabolic equivalents)
- • 6) discharged from formal rehabilitation
- Exclusion Criteria:
- • 1) significant resting ECG abnormalities
- • 2) evidence of significant arrhythmia or myocardial ischemia on treadmill ECG stress test
- • 3) hospitalization for cardiac or pulmonary disease within 3 months
- • 4) pacemaker or implanted defibrillator
- • 5) lower extremity claudication
- • 6) unable to communicate with investigators or correctly answer consent comprehension questions
- • 7) severe lower extremity spasticity (Ashworth \>2)
- • 8) lower extremity weight bearing pain \>4/10 on visual analogue scale
- • For the transcranial magnetic stimulation substudy, additional exclusions will also be applied. These include large cerebral infarcts or other structural defects with the potential to increase seizure risk, uncontrolled seizures, metal implants and previous craniotomy.
About University Of Cincinnati
The University of Cincinnati is a leading research institution dedicated to advancing healthcare through innovative clinical trials and studies. With a robust focus on translational research, the university fosters a collaborative environment that integrates cutting-edge science with clinical practice. Its diverse team of experts, equipped with state-of-the-art facilities, is committed to exploring new therapeutic interventions aimed at improving patient outcomes. The University of Cincinnati actively engages in partnerships with industry and academia to drive forward-thinking solutions in medicine, ensuring that research findings are effectively translated into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Patients applied
Trial Officials
Brett Kissela, MD
Principal Investigator
University of Cincinnati
Kari Dunning, PhD, PT
Principal Investigator
University of Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials